@article { ISI:000381593700007,
	title = {Spectroscopy and catalytic activity study of gold supported on barium titanate nanotubes for styrene epoxidation},
	journal = {Applied Catalysis A-General},
	volume = {523},
	year = {2016},
	month = {AUG},
	pages = {61-72},
	publisher = {ELSEVIER SCIENCE BV},
	address = {PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS},
	abstract = {<p>Gold (0.5-5 wt.\%) supported on barium titanate nanotubes (Au/BaTNT) were prepared, characterized and for the first time, investigated as catalysts for selective oxidation of styrene with oxygen (O-2 or H-2 + O-2) and peroxides (H2O2 or TBHP). Conversion of styrene enhanced when H-2 was co-added to O-2 in the reactions. Au/BaTNT activated O-2 and H-2 and produced H2O2 in situ for use in oxidations. Peroxides were found better oxidants than O-2. At optimized conditions, styrene oxide selectivity of 80.1 wt.\% at styrene conversion of 60.5 wt.\% was achieved over Au(1 wt.\%)/BaTNT using TBHP. Au particles (5.0-7.4 nm) were dispersed and decorated on the walls of BaTNT. They exhibited superior performance to the known Au catalysts in styrene oxidation. Reactive oxygen species formed during oxidation reactions were followed with in situ spectral characterizations (diffuse reflectance UV-vis and FT -Raman). Au/BaTNT was reusable in four recycles with little loss in catalytic activity. (C) 2016 Elsevier B.V. All rights reserved.</p>},
	keywords = {Au Nanoparticles, reactive oxygen species, spectroscopy, Styrene Oxidation, Titanate nanotubes},
	issn = {0926-860X},
	doi = {10.1016/j.apcata.2016.05.014},
	author = {Nepak, Devadutta and Srinivas, Darbha}
}
@article {44024,
	title = {Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model},
	journal = {International Journal of Nanomedicine},
	volume = {12},
	year = {2017},
	month = {AUG},
	pages = { 6357-6364},
	type = {Journal Article},
	abstract = {Around 40\% of high-risk prostate cancer patients who undergo radiotherapy (RT) will experience biochemical failure. Chemotherapy, such as docetaxel (DTX), can enhance the efficacy of RT. Multidrug resistance mechanisms often limit drug efficacy by decreasing intracellular concentrations of drugs in tumor cells. It is, therefore, of interest to develop nanocarriers of DTX to maintain the drug inside cancer cells and thus improve treatment efficacy. The purpose of this study was to investigate the use of titanate nanotubes (TiONts) to develop a TiONts-DTX nanocarrier and to evaluate its radiosensitizing in vivo efficacy in a prostate cancer model. In vitro cytotoxic activity of TiONts-DTX was evaluated using an MTS assay. The biodistribution of TiONts-DTX was analyzed in vivo by single-photon emission computed tomography. The benefit of TiONts-DTX associated with RT was evaluated in vivo. Eight groups with seven mice in each were used to evaluate the efficacy of the nanohybrid combined with RT: control with buffer IT injection {\textpm} RT, free DXL {\textpm} RT, TiONts {\textpm} RT and TiONts-DXL {\textpm} RT. Mouse behavior, health status and tumor volume were monitored twice a week until the tumor volume reached a maximum of 2,000 mm3. More than 70\% of nanohybrids were localized inside the tumor 96 h after administration. Tumor growth was significantly slowed by TiONts-DTX associated with RT, compared with free DTX in the same conditions (P=0.013). These results suggest that TiONts-DTX improved RT efficacy and might enhance local control in high-risk localized prostate cancer.},
	keywords = {Docetaxel Nanocarrier, nanoparticle, Prostate Cancer, Radiosensitivity, Titanate nanotubes},
	doi = {10.2147/IJN.S139167},
	author = {Mirjolet, C. and Martin, E. and Boudon, J. and Loiseau, A. and Chevrier, S. and Boidot, R. and Oudot, A. and Collin, B. and Joy, P. A. and Millot, N. and Cr{\'e}hange, G.}
}
